Dogwood Therapeutics Files 8-K: Regulation FD Disclosure
Ticker: DWTX · Form: 8-K · Filed: Mar 26, 2026 · CIK: 0001818844
| Field | Detail |
|---|---|
| Company | Dogwood Therapeutics, INC. (DWTX) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2026 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: regulation-fd, disclosure, corporate-action
TL;DR
**Dogwood Therapeutics just dropped an 8-K, likely big news coming!**
AI Summary
Dogwood Therapeutics, Inc. filed an 8-K on March 26, 2026, under Item 7.01, Regulation FD Disclosure, indicating they are making a public announcement of material non-public information. This filing suggests the company is proactively sharing important news, likely to ensure fair and broad dissemination to all investors. For shareholders, this means new information about the company's operations or financial health is now available, which could influence the stock's future performance.
Why It Matters
This filing signals that Dogwood Therapeutics is releasing significant, previously non-public information, which could impact investor perception and stock valuation.
Risk Assessment
Risk Level: low — An 8-K filing for Regulation FD Disclosure is a standard procedure for transparent communication, not inherently risky.
Analyst Insight
A smart investor would monitor Dogwood Therapeutics' news releases closely for the specific details of the Regulation FD disclosure to understand its potential impact on the company's valuation.
Key Numbers
- 8-K — Form Type (The specific SEC form filed by Dogwood Therapeutics, Inc.)
- 7.01 — Item Number (The specific item under which the disclosure is made, indicating Regulation FD Disclosure.)
- 0001104659-26-034928 — Accession Number (Unique identifier for this specific SEC filing.)
Key Players & Entities
- Dogwood Therapeutics, Inc. (company) — the filer of the 8-K
- 0001818844 (person) — CIK of Dogwood Therapeutics, Inc.
- 2026-03-26 (dollar_amount) — filing date and period of report
Forward-Looking Statements
- Dogwood Therapeutics will release specific details of the disclosed information within the next few days. (Dogwood Therapeutics, Inc.) — high confidence, target: 2026-03-29
- The stock price of Dogwood Therapeutics will react to the content of the Regulation FD disclosure. (Dogwood Therapeutics, Inc.) — medium confidence, target: 2026-03-27
FAQ
What is the primary purpose of Dogwood Therapeutics, Inc.'s 8-K filing on March 26, 2026?
The primary purpose of Dogwood Therapeutics, Inc.'s 8-K filing on March 26, 2026, is to disclose information under Item 7.01, Regulation FD Disclosure, meaning they are making a public announcement of material non-public information.
When was this 8-K filing accepted by the SEC?
This 8-K filing was accepted by the SEC on March 26, 2026, at 09:00:12.
What is the CIK number for Dogwood Therapeutics, Inc.?
The CIK number for Dogwood Therapeutics, Inc. is 0001818844.
What is the business address listed for Dogwood Therapeutics, Inc. in this filing?
The business address listed for Dogwood Therapeutics, Inc. is 44 MILTON AVENUE, ALPHARETTA, GA 30009.
Which SIC code is associated with Dogwood Therapeutics, Inc. in this filing?
Dogwood Therapeutics, Inc. is associated with SIC code 2834, which represents Pharmaceutical Preparations.
Filing Stats: 516 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2026-03-26 09:00:12
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 DWTX Nasdaq Capital Market Check t
Filing Documents
- dwtx-20260326x8k.htm (8-K) — 40KB
- dwtx-20260326xex99d1.htm (EX-99.1) — 24KB
- dwtx-20260326xex99d1002.jpg (GRAPHIC) — 5KB
- 0001104659-26-034928.txt ( ) — 181KB
- dwtx-20260326.xsd (EX-101.SCH) — 3KB
- dwtx-20260326_lab.xml (EX-101.LAB) — 15KB
- dwtx-20260326_pre.xml (EX-101.PRE) — 9KB
- dwtx-20260326x8k_htm.xml (XML) — 5KB
01
Item 7.01 Regulation FD Disclosure. On March 26, 2026, the Company posted a shareholder letter to its website providing a corporate update. A copy of the shareholder letter is furnished as Exhibit 99.1. The information in Item 7.01 of this Current Report on Form 8-K, including the information in the shareholder letter attached as Exhibit 99.1 to this Current Report on Form 8-K is furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section. Furthermore, the information in Item 7.01 of this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit Number Description 99.1 Shareholder letter , dated March 26, 2026 (furnished herewith). 104 Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DOGWOOD THERAPEUTICS, INC. By: /s/ Angela Walsh Name: Angela Walsh Title: Chief Financial Officer, Corporate Secretary and Treasurer March 26, 2026 3